Abiraterone is an inhibitor of androgen biosynthesis indicated for the treatment of metastatic castration-resistant prostate cancer. Common side effects include diarrhea, edema, hypokalemia, hypertension, and liver function test abnormalities. We report a case of rhabdomyolysis developing in association with the use of abiraterone. Following discontinuation of abiraterone, creatine kinase concentrations decreased gradually throughout the duration of the hospitalization.
Beckett RD, Rodeffer KM and Snodgrass R. Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother 2012; 46: 1016–1024.
11.
Mohler JL, Armstrong AJ, Bahnson RR, et al. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: prostate cancer. www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed 20 July 2015).
